Complexities of oestrogen in stroke

Clinical Science

Volumn 118, Issue 6, 2010, Pages 375-389

  Carswell, Hillary V O ^a   Macrae, I Mhairi ^b   Farr, Tracy D ^b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Cardiovascular disease; Cerebrovascular system; Hormone replacement therapy; Oestrogen; Selective oestrogen receptor modulator (SERM); Stroke

Indexed keywords

1,3,5 TRIS(4 HYDROXYPHENYL) 4 PROPYLPYRAZOLE; 4 AMINOBUTYRIC ACID; ARZOXIFENE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DIARYLPROPIOLNITRILE; DISUFENTON SODIUM; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; GESTAGEN; GESTODENE; MEDROXYPROGESTERONE ACETATE; MESSENGER RNA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; NORGESTREL; PHYTOESTROGEN; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TIBOLONE; UNCLASSIFIED DRUG; WAY 2000703;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BRAIN ISCHEMIA; BREAST CANCER; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; DEMENTIA; DRUG MEGADOSE; DRUG SCREENING; ESTROGEN ACTIVITY; ESTROGEN DEFICIENCY; ESTRUS; EXCITOTOXICITY; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID PEROXIDATION; LOW DRUG DOSE; MIDDLE CEREBRAL ARTERY OCCLUSION; MILD COGNITIVE IMPAIRMENT; NEUROPROTECTION; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE; SYNAPTOGENESIS; VEIN THROMBOSIS;

ANIMALS; CASTRATION; COGNITION DISORDERS; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; LIPIDS; MALE; MICE; NOOTROPIC AGENTS; POSTMENOPAUSE; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STROKE; VENOUS THROMBOSIS;

EID: 73149094946     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20090018     Document Type: Review

References (176)

1. Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., Jackson, R. D., Beresford, S. A., Howard, B. V., Johnson, K. C. et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women';s Health Initiative randomized controlled trial. JAMA, J. Am. Med. Assoc. 288, 321-333
2. Garcia-Segura, L. M., Azcoitia, I. and DonCarlos, L. L. (2001) Neuroprotection by estradiol. Prog. Neurobiol. 63, 29-60
3. Hurn, P. D. and Brass, L. M. (2003) Estrogen and stroke: a balanced analysis. Stroke 34, 338-341
4. Hurn, P. D. and Macrae, I. M. (2000) Estrogen as a neuroprotectant in stroke. J. Cereb. Blood Flow. Metab. 20, 631-652
5. Murphy, S. J., McCullough, L. D. and Smith, J. M. (2004) Stroke in the female: role of biological sex and estrogen. ILAR J. 45, 147-159
6. Gibson, C. L., Gray, L. J., Murphy, S. P. and Bath, P. M. (2006) Estrogens and experimental ischemic stroke: a systematic review. J. Cereb. Blood Flow. Metab. 26, 1103-1113
7. Carswell, H. V., Dominiczak, A. F. and Macrae, I. M. (2000) Estrogen status affects sensitivity to focal cerebral ischemia in stroke-prone spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. 278, H290-H294
8. Liao, S., Chen, W., Kuo, J. and Chen, C. (2001) Association of serum estrogen level and ischemic neuroprotection in female rats. Neurosci. Lett. 297, 159-162
9. Alkayed, N. J., Harukuni, I., Kimes, A. S., London, E. D., Traystman, R. J. and Hurn, P. D. (1998) Gender-linked brain injury in experimental stroke. Stroke 29, 159-165
10. Alkayed, N. J., Murphy, S. J., Traystman, R. J., Hurn, P. D. and Miller, V. M. (2000) Neuroprotective effects of female gonadal steroids in reproductively senescent female rats. Stroke 31, 161-168
11. Dubal, D. B., Kashon, M. L., Pettigrew, L. C., Ren, J. M., Finklestein, S. P., Rau, S. W. and Wise, P. M. (1998) Estradiol protects against ischemic injury. J. Cereb. Blood Flow. Metab. 18, 1253-1258
12. Fan, T., Yang, S. H., Johnson, E., Osteen, B., Hayes, R., Day, A. L. and Simpkins, J.W. (2003) 17β-Estradiol extends ischemic thresholds and exerts neuroprotective effects in cerebral subcortex against transient focal cerebral ischemia in rats. Brain Res. 993, 10-17
13. Fukuda, K., Yao, H., Ibayashi, S., Nakahara, T., Uchimura, H., Fujishima, M. and Hall, E. D. (2000) Ovariectomy exacerbates and estrogen replacement attenuates photothrombotic focal ischemic brain injury in rats. Stroke 31, 155-160
14. He, Z., He, Y. J., Day, A. L. and Simpkins, J.W. (2002) Proestrus levels of estradiol during transient global cerebral ischemia improves the histological outcome of the hippocampal CA1 region: perfusion-dependent and-independent mechanisms. J. Neurol. Sci. 193, 79-87
15. Horsburgh, K., Macrae, I. M. and Carswell, H. (2002) Estrogen is neuroprotective via an apolipoprotein E-dependent mechanism in a mouse model of global ischemia. J. Cereb. Blood Flow. Metab. 22, 1189-1195
16. Rau, S. W., Dubal, D. B., Bottner, M., Gerhold, L. M. and Wise, P. M. (2003) Estradiol attenuates programmed cell death after stroke-like injury. J. Neurosci. 23, 11420-11426
17. Rusa, R., Alkayed, N. J., Crain, B. J., Traystman, R. J., Kimes, A. S., London, E. D., Klaus, J. A. and Hurn, P. D. (1999) 17β-Estradiol reduces stroke injury in estrogen-deficient female animals. Stroke 30, 1665-1670
18. Shi, J., Bui, J. D., Yang, S. H., He, Z., Lucas, T. H., Buckley, D. L., Blackband, S. J., King, M. A., Day, A. L. and Simpkins, J.W. (2001) Estrogens decrease reperfusion-associated cortical ischemic damage: an MRI analysis in a transient focal ischemia model. Stroke 32, 987-992
19. Simpkins, J.W., Rajakumar, G., Zhang, Y. Q., Simpkins, C. E., Greenwald, D., Yu, C. J., Bodor, N. and Day, A. L. (1997) Estrogens may reduce mortality and ischemic damage caused by middle cerebral artery occlusion in the female rat. J. Neurosurg. 87, 724-730
20. Wang, Q., Santizo, R., Baughman, V. L., Pelligrino, D. A. and Iadecola, C. (1999) Estrogen provides neuroprotection in transient forebrain ischemia through perfusion-independent mechanisms in rats. Stroke 30, 630-637
21. Wise, P. M. and Dubal, D. B. (2000) Estradiol protects against ischemic brain injury in middle-aged rats. Biol. Reprod. 63, 982-985
22. Yang, S. H., Shi, J., Day, A. L. and Simpkins, J.W. (2000) Estradiol exerts neuroprotective effects when administered after ischemic insult. Stroke 31, 745-749
23. Zhang, Y. Q., Shi, J., Rajakumar, G., Day, A. L. and Simpkins, J.W. (1998) Effects of gender and estradiol treatment on focal brain ischemia. Brain Res. 784, 321-324
24. Hawk, T., Zhang, Y. Q., Rajakumar, G., Day, A. L. and Simpkins, J.W. (1998) Testosterone increases and estradiol decreases middle cerebral artery occlusion lesion size in male rats. Brain Res. 796, 296-298
25. Toung, T. J., Traystman, R. J. and Hurn, P. D. (1998) Estrogen-mediated neuroprotection after experimental stroke in male rats. Stroke 29, 1666-1670
26. Vergouwen, M. D., Anderson, R. E. and Meyer, F. B. (2000) Gender differences and the effects of synthetic exogenous and non-synthetic estrogens in focal cerebral ischemia. Brain Res. 878, 88-97
27. Bingham, D., Macrae, I. M. and Carswell, H. V. (2005) Detrimental effects of 17β-Oestradiol after permanent middle cerebral artery occlusion. J. Cereb. Blood Flow. Metab. 25, 414-420
28. Carswell, H. V., Bingham, D., Wallace, K., Nilsen, M., Graham, D. I., Dominiczak, A. F. and Macrae, I. M. (2004) Differential effects of 17β-estradiol upon stroke damage in stroke prone and normotensive rats. J. Cereb. Blood Flow. Metab. 24, 298-304
29. Gordon, K. B., Macrae, I. M. and Carswell, H. V. (2005) Effects of 17β-oestradiol on cerebral ischaemic damage and lipid peroxidation. Brain Res. 1036, 155-162
30. Harukuni, I., Hurn, P. D. and Crain, B. J. (2001) Deleterious effect of β-estradiol in a rat model of transient forebrain ischemia. Brain Res. 900, 137-142
31. Theodorsson, A. and Theodorsson, E. (2005) Estradiol increases brain lesions in the cortex and lateral striatum after transient occlusion of the middle cerebral artery in rats: no effect of ischemia on galanin in the stroke area but decreased levels in the hippocampus. Peptides 26, 2257-2264
32. Yong, Y., Xie, H. J., Zhang, Y. F., Yang, Q. D., Liao, D. F., Yang, H. L., Yan, P. K. and Liu, Z. J. (2005) 17β-Estradiol potentiates ischemia-reperfusion injury in diabetic ovariectomized female rats. Brain Res. 1054, 192-199
33. Santizo, R. A., Xu, H. L., Ye, S., Baughman, V. L. and Pelligrino, D. A. (2002) Loss of benefit from estrogen replacement therapy in diabetic ovariectomized female rats subjected to transient forebrain ischemia. Brain Res. 956, 86-95
34. Zhang, L., Nair, A., Krady, K., Corpe, C., Bonneau, R. H., Simpson, I. A. and Vannucci, S. J. (2004) Estrogen stimulates microglia and brain recovery from hypoxia-ischemia in normoglycemic but not diabetic female mice. J. Clin. Invest. 113, 85-95
35. Wang, L., Kitano, H., Hurn, P. D. and Murphy, S. J. (2008) Estradiol attenuates neuroprotective benefits of isoflurane preconditioning in ischemic mouse brain. J. Cereb. Blood Flow. Metab. 28, 1824-1834
36. Kim, H. P., Lee, J. Y., Jeong, J. K., Bae, S. W., Lee, H. K. and Jo, I. (1999) Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor α localized in caveolae. Biochem. Biophys. Res. Commun. 263, 257-262
37. Farhat, M. Y., Lavigne, M. C. and Ramwell, P. W. (1996) The vascular protective effects of estrogen. FASEB J. 10, 615-624
38. Chen, Z., Yuhanna, I. S., Galcheva-Gargova, Z., Karas, R. H., Mendelsohn, M. E. and Shaul, P.W. (1999) Estrogen receptor a mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J. Clin. Invest. 103, 401-406
39. McNeill, A. M., Kim, N., Duckles, S. P., Krause, D. N. and Kontos, H. A. (1999) Chronic estrogen treatment increases levels of endothelial nitric oxide synthase protein in rat cerebral microvessels. Stroke 30, 2186-2190
40. McCullough, L. D., Alkayed, N. J., Traystman, R. J., Williams, M. J. and Hurn, P. D. (2001) Postischemic estrogen reduces hypoperfusion and secondary ischemia after experimental stroke. Stroke 32, 796-802
41. Pelligrino, D. A., Santizo, R., Baughman, V. L. and Wang, Q. (1998) Cerebral vasodilating capacity during forebrain ischemia: effects of chronic estrogen depletion and repletion and the role of neuronal nitric oxide synthase. Neuroreport 9, 3285-3291
42. Hurn, P. D., Littleton-Kearney, M. T., Kirsch, J. R., Dharmarajan, A. M. and Traystman, R. J. (1995) Postischemic cerebral blood flow recovery in the female: effect of 17 β-estradiol. J. Cereb. Blood Flow. Metab. 15, 666-672
43. Simpkins, J. W., Yang, S. H., Liu, R., Perez, E., Cai, Z. Y., Covey, D. F. and Green, P. S. (2004) Estrogen-like compounds for ischemic neuroprotection. Stroke 35, 2648-2651
44. Behl, C. and Holsboer, F. (1999) The female sex hormone oestrogen as a neuroprotectant. Trends Pharmacol Sci. 20, 441-444
45. Culmsee, C., Vedder, H., Ravati, A., Junker, V., Otto, D., Ahlemeyer, B., Krieg, J. C. and Krieglstein, J. (1999) Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: evidence for a receptor-independent antioxidative mechanism. J. Cereb. Blood Flow. Metab. 19, 1263-1269
46. Behl, C., Skutella, T., Lezoualc'h, F., Post, A., Widmann, M., Newton, C. J. and Holsboer, F. (1997) Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol. Pharmacol. 51, 535-541
47. Vedder, H., Anthes, N., Stumm, G., Wurz, C., Behl, C. and Krieg, J. C. (1999) Estrogen hormones reduce lipid peroxidation in cells and tissues of the central nervous system. J. Neurochem. 72, 2531-2538
48. Ayres, S., Abplanalp, W., Liu, J. H. and Subbiah, M. T. (1998) Mechanisms involved in the protective effect of estradiol-17β on lipid peroxidation and DNA damage. Am. J. Physiol. 274, E1002-E1008
49. Subbiah, M. T., Kessel, B., Agrawal, M., Rajan, R., Abplanalp, W. and Rymaszewski, Z. (1993) Antioxidant potential of specific estrogens on lipid peroxidation. J. Clin. Endocrinol. Metab. 77, 1095-1097
50. Sawada, H., Ibi, M., Kihara, T., Urushitani, M., Honda, K., Nakanishi, M., Akaike, A. and Shimohama, S. (2000) Mechanisms of antiapoptotic effects of estrogens in nigral dopaminergic neurons. FASEB J. 14, 1202-1214
51. Czlonkowska, A., Ciesielska, A., Gromadzka, G. and Kurkowska-Jastrzebska, I. (2006) Gender differences in neurological disease: role of estrogens and cytokines. Endocrine 29, 243-256
52. Dimayuga, F.O., Reed, J. L., Carnero, G. A., Wang, C., Dimayuga, E. R., Dimayuga, V. M., Perger, A., Wilson, M. E., Keller, J. N. and Bruce-Keller, A. J. (2005) Estrogen and brain inflammation: effects on microglial expression of MHC, costimulatory molecules and cytokines. J. Neuroimmunol. 161, 123-136
53. Jean, W. C., Spellman, S. R., Nussbaum, E. S. and Low, W. C. (1998) Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery 43, 1382-1396
54. Marriott, L. K., Hauss-Wegrzyniak, B., Benton, R. S., Vraniak, P. D. and Wenk, G. L. (2002) Long-term estrogen therapy worsens the behavioral and neuropathological consequences of chronic brain inflammation. Behav. Neurosci. 116, 902-911
55. Xu, H. L., Baughman, V. L. and Pelligrino, D. A. (2004) Estrogen replacement treatment in diabetic ovariectomized female rats potentiates postischemic leukocyte adhesion in cerebral venules. Stroke 35, 1974-1978
56. Suzuki, S., Brown, C. M., Dela Cruz, C. D., Yang, E., Bridwell, D. A. and Wise, P. M. (2007) Timing of estrogen therapy after ovariectomy dictates the efficacy of its neuroprotective and antiinflammatory actions. Proc. Natl. Acad. Sci. U.S.A. 104, 6013-6018
57. Brann, D.W., Zamorano, P. L., Chorich, L. P. and Mahesh, V. B. (1993) Steroid hormone effects on NMDA receptor binding and NMDA receptor mRNA levels in the hypothalamus and cerebral cortex of the adult rat. Neuroendocrinology 58, 666-672
58. Woolley, C. S.,Weiland, N. G., McEwen, B. S. and Schwartzkroin, P. A. (1997) Estradiol increases the sensitivity of hippocampal CA1 pyramidal cells to NMDA receptor-mediated synaptic input: correlation with dendritic spine density. J. Neurosci. 17, 1848-1859
59. Pozzo-Miller, L. D., Inoue, T. and Murphy, D. D. (1999) Estradiol increases spine density and NMDA-dependent Ca2+ transients in spines of CA1 pyramidal neurons from hippocampal slices. J. Neurophysiol. 81, 1404-1411
60. Sato, K., Matsuki, N., Ohno, Y. and Nakazawa, K. (2003) Estrogens inhibit l-glutamate uptake activity of astrocytes via membrane estrogen receptor a. J. Neurochem. 86, 1498-1505
61. Strom, J. O., Theodorsson, A. and Theodorsson, E. (2009) Dose-related neuroprotective versus neurodamaging effects of estrogens in rat cerebral ischemia: a systematic analysis. J. Cereb. Blood Flow. Metab. 29, 1359-1372
62. Shughrue, P. J., Lane, M. V. and Merchenthaler, I. (1997) Comparative distribution of estrogen receptor-α and -β mRNA in the rat central nervous system. J. Comp. Neurol. 388, 507-525
63. Kuiper, G. G. and Gustafsson, J. A. (1997) The novel estrogen receptor-β subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett. 410, 87-90
64. Kuiper, G. G., Shughrue, P. J., Merchenthaler, I. and Gustafsson, J. A. (1998) The estrogen receptor β subtype: a novel mediator of estrogen action in neuroendocrine systems. Front. Neuroendocrinol. 19, 253-286
65. Harrington, W. R., Sheng, S., Barnett, D. H., Petz, L. N., Katzenellenbogen, J. A. and Katzenellenbogen, B. S. (2003) Activities of estrogen receptor α- and β-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression. Mol. Cell. Endocrinol. 206, 13-22
66. Curtis Hewitt, S., Couse, J. F. and Korach, K. S. (2000) Estrogen receptor transcription and transactivation: estrogen receptor knockout mice - what their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Res. 2, 345-352
67. van de Stolpe, A., Slycke, A. J., Reinders, M. O., Zomer, A.W., Goodenough, S., Behl, C., Seasholtz, A. F. and van der Saag, P. T. (2004) Estrogen receptor (ER)-mediated transcriptional regulation of the human corticotropin-releasing hormone-binding protein promoter: differential effects of ERα and ERβ. Mol. Endocrinol. 18, 2908-2923
68. Sawada, M., Alkayed, N. J., Goto, S., Crain, B. J., Traystman, R. J., Shaivitz, A., Nelson, R. J. and Hurn, P. D. (2000) Estrogen receptor antagonist ICI182,780 exacerbates ischemic injury in female mouse. J. Cereb. Blood Flow. Metab. 20, 112-118
69. Miller, N. R., Jover, T., Cohen, H. W., Zukin, R. S. and Etgen, A. M. (2005) Estrogen can act via estrogen receptor α and β to protect hippocampal neurons against global ischemia-induced cell death. Endocrinology 146, 3070-3079
70. Carswell, H. V., Macrae, I. M., Gallagher, L., Harrop, E. and Horsburgh, K. J. (2004) Neuroprotection by a selective estrogen receptor β agonist in a mouse model of global ischemia. Am. J. Physiol. Heart Circ. Physiol. 287, H1501-H1504
71. Dai, X., Chen, L. and Sokabe, M. (2007) Neurosteroid estradiol rescues ischemia-induced deficit in the long-term potentiation of rat hippocampal CA1 neurons. Neuropharmacology 52, 1124-1138
72. Farr, T. D., Carswell, H. V., Gsell, W. and Macrae, I. M. (2007) Estrogen receptor β agonist diarylpropiolnitrile (DPN) does not mediate neuroprotection in a rat model of permanent focal ischemia. Brain Res. 1185, 275-282
73. Sampei, K., Goto, S., Alkayed, N. J., Crain, B. J., Korach, K. S., Traystman, R. J., Demas, G. E., Nelson, R. J. and Hurn, P. D. (2000) Stroke in estrogen receptor-α-deficient mice. Stroke 31, 738-743
74. Dubal, D. B., Zhu, H., Yu, J., Rau, S.W., Shughrue, P. J., Merchenthaler, I., Kindy, M. S. and Wise, P. M. (2001) Estrogen receptor α, not β, is a critical link in estradiol-mediated protection against brain injury. Proc. Natl. Acad. Sci. U.S.A. 98, 1952-1957
75. Dubal, D. B., Rau, S. W., Shughrue, P. J., Zhu, H., Yu, J., Cashion, A. B., Suzuki, S., Gerhold, L. M., Bottner, M. B., Dubal, S. B. et al. (2006) Differential modulation of estrogen receptors (ERs) in ischemic brain injury: a role for ERa in estradiol-mediated protection against delayed cell death. Endocrinology 147, 3076-3084
76. Cordoba Montoya, D. A. and Carrer, H. F. (1997) Estrogen facilitates induction of long term potentiation in the hippocampus of awake rats. Brain Res. 778, 430-438
77. Warren, S. G., Humphreys, A. G., Juraska, J. M. and Greenough, W. T. (1995) LTP varies across the estrous cycle: enhanced synaptic plasticity in proestrus rats. Brain Res. 703, 26-30
78. Weiland, N. G. (1992) Estradiol selectively regulates agonist binding sites on the N-methyl-D-aspartate receptor complex in the CA1 region of the hippocampus. Endocrinology 131, 662-668
79. Foy, M. R., Xu, J., Xie, X., Brinton, R. D., Thompson, R. F. and Berger, T.W. (1999) 17β-Estradiol enhances NMDA receptor-mediated EPSPs and long-term potentiation. J. Neurophysiol. 81, 925-929
80. Murphy, D. D. and Andrews, S. B. (2000) Culture models for the study of estradiol-induced synaptic plasticity. J. Neurocytol. 29, 411-417
81. Woolley, C. S. (1998) Estrogen-mediated structural and functional synaptic plasticity in the female rat hippocampus. Horm. Behav. 34, 140-148
82. Gould, E., Woolley, C. S., Frankfurt, M. and McEwen, B. S. (1990) Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J. Neurosci. 10, 1286-1291
83. Woolley, C. S., Gould, E., Frankfurt, M. and McEwen, B. S. (1990) Naturally occurring fluctuation in dendritic spine density on adult hippocampal pyramidal neurons. J. Neurosci. 10, 4035-4039
84. Garcia-Segura, L. M., Chowen, J. A., Parducz, A. and Naftolin, F. (1994) Gonadal hormones as promoters of structural synaptic plasticity: cellular mechanisms. Prog. Neurobiol. 44, 279-307
85. Brake, W. G., Alves, S. E., Dunlop, J. C., Lee, S. J., Bulloch, K., Allen, P. B., Greengard, P. and McEwen, B. S. (2001) Novel target sites for estrogen action in the dorsal hippocampus: an examination of synaptic proteins. Endocrinology 142, 1284-1289
86. Choi, J. M., Romeo, R. D., Brake, W. G., Bethea, C. L., Rosenwaks, Z. and McEwen, B. S. (2003) Estradiol increases pre- and post-synaptic proteins in the CA1 region of the hippocampus in female rhesus macaques (Macaca mulatta). Endocrinology 144, 4734-4738
87. Murphy, D. D. and Segal, M. (1996) Regulation of dendritic spine density in cultured rat hippocampal neurons by steroid hormones. J. Neurosci. 16, 4059-4068
88. Weiland, N. G., Orikasa, C., Hayashi, S. and McEwen, B. S. (1997) Distribution and hormone regulation of estrogen receptor immunoreactive cells in the hippocampus of male and female rats. J. Comp. Neurol. 388, 603-612
89. Hart, S. A., Patton, J. D. and Woolley, C. S. (2001) Quantitative analysis of ER a and GAD colocalization in the hippocampus of the adult female rat. J. Comp. Neurol. 440, 144-155
90. Rudick, C. N. and Woolley, C. S. (2001) Estrogen regulates functional inhibition of hippocampal CA1 pyramidal cells in the adult female rat. J. Neurosci. 21, 6532-6543
91. Gibbs, R. B. (2000) Long-term treatment with estrogen and progesterone enhances acquisition of a spatial memory task by ovariectomized aged rats. Neurobiol. Aging 21, 107-116
92. Daniel, J. M., Roberts, S. L. and Dohanich, G. P. (1999) Effects of ovarian hormones and environment on radial maze and water maze performance of female rats. Physiol. Behav. 66, 11-20
93. O'Neal, M. F., Means, L.W., Poole, M. C. and Hamm, R. J. (1996) Estrogen affects performance of ovariectomized rats in a two-choice water-escape working memory task. Psychoneuroendocrinology 21, 51-65
94. Packard, M. G. and Teather, L. A. (1997) Posttraining estradiol injections enhance memory in ovariectomized rats: cholinergic blockade and synergism. Neurobiol. Learn. Mem. 68, 172-188
95. Rissanen, A., Puolivali, J., van Groen, T. and Riekkinen, Jr, P. (1999) In mice tonic estrogen replacement therapy improves non-spatial and spatial memory in a water maze task. Neuroreport 10, 1369-1372
96. Heikkinen, T., Puolivali, J., Liu, L., Rissanen, A. and Tanila, H. (2002) Effects of ovariectomy and estrogen treatment on learning and hippocampal neurotransmitters in mice. Horm. Behav. 41, 22-32
97. Bimonte, H. A. and Denenberg, V. H. (1999) Estradiol facilitates performance as working memory load increases. Psychoneuroendocrinology 24, 161-173
98. Fader, A. J., Johnson, P. E. and Dohanich, G. P. (1999) Estrogen improves working but not reference memory and prevents amnestic effects of scopolamine of a radial-arm maze. Pharmacol. Biochem. Behav. 62, 711-717
99. Luine, V. N., Jacome, L. F. and Maclusky, N. J. (2003) Rapid enhancement of visual and place memory by estrogens in rats. Endocrinology 144, 2836-2844
100. Lannert, H.,Wirtz, P., Schuhmann, V. and Galmbacher, R. (1998) Effects of estradiol (-17β) on learning, memory and cerebral energy metabolism in male rats after intracerebroventricular administration of streptozotocin. J. Neural Transm. 105, 1045-1063
101. Sandstrom, N. J. and Williams, C. L. (2001) Memory retention is modulated by acute estradiol and progesterone replacement. Behav. Neurosci. 115, 384-393
102. Frick, K. M., Fernandez, S. M. and Bulinski, S. C. (2002) Estrogen replacement improves spatial reference memory and increases hippocampal synaptophysin in aged female mice. Neuroscience 115, 547-558
103. Li, C., Brake, W. G., Romeo, R. D., Dunlop, J. C., Gordon, M., Buzescu, R., Magarinos, A. M., Allen, P. B., Greengard, P., Luine, V. and McEwen, B. S. (2004) Estrogen alters hippocampal dendritic spine shape and enhances synaptic protein immunoreactivity and spatial memory in female mice. Proc. Natl. Acad. Sci. U.S.A. 101, 2185-2190
104. Li, X., Blizzard, K. K., Zeng, Z., DeVries, A. C., Hurn, P. D. and McCullough, L. D. (2004) Chronic behavioral testing after focal ischemia in the mouse: functional recovery and the effects of gender. Exp. Neurol. 187, 94-104
105. Farr, T. D., Carswell, H. V., Gallagher, L., Condon, B., Fagan, A. J., Mullin, J. and Macrae, I. M. (2006) 17β-Estradiol treatment following permanent focal ischemia does not influence recovery of sensorimotor function. Neurobiol. Dis. 23, 552-562
106. Auriat, A., Plahta, W. C., McGie, S. C., Yan, R. and Colbourne, F. (2005) 17β-Estradiol pretreatment reduces bleeding and brain injury after intracerebral hemorrhagic stroke in male rats. J. Cereb. Blood Flow. Metab. 25, 247-256
107. Nguyen, A. P., Arvanitidis, A. P. and Colbourne, F. (2008) Failure of estradiol to improve spontaneous or rehabilitation-facilitated recovery after hemorrhagic stroke in rats. Brain Res. 1193, 109-119
108. Katzenellenbogen, B. S. and Katzenellenbogen, J. A. (2002) Biomedicine: defining the "S" in SERMs. Science 295, 2380-2381
109. Littleton-Kearney, M. T., Ostrowski, N. L., Cox, D. A., Rossberg, M. I. and Hurn, P. D. (2002) Selective estrogen receptor modulators: tissue actions and potential for CNS protection. CNS Drug Rev. 8, 309-330
110. Murphy, S., McCullough, L., Littleton-Kearney, M. and Hurn, P. (2003) Estrogen and selective estrogen receptor modulators: neuroprotection in the Women's Health Initiative era. Endocrine 21, 17-26
111. Lewis, J. S. and Jordan, V. C. (2005) Selective estrogen receptor modulators (SERMs): Mechanisms of anticarcinogenesis and drug resistance. Mutat. Res. 591, 247-263
112. Ciriza, I., Carrero, P., Azcoitia, I., Lundeen, S. G. and Garcia-Segura, L. M. (2004) Selective estrogen receptor modulators protect hippocampal neurons from kainic acid excitotoxicity: differences with the effect of estradiol. J. Neurobiol. 61, 209-221
113. Du, B., Ohmichi, M., Takahashi, K., Kawagoe, J., Ohshima, C., Igarashi, H., Mori-Abe, A., Saitoh, M., Ohta, T., Ohishi, A. et al. (2004) Both estrogen and raloxifene protect against β-amyloid-induced neurotoxicity in estrogen receptor α-transfected PC12 cells by activation of telomerase activity via Akt cascade. J. Endocrinol. 183, 605-615
114. Grandbois, M., Morissette, M., Callier, S. and Di Paolo, T. (2000) Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Neuroreport 11, 343-346
115. Callier, S., Morissette, M., Grandbois, M., Pelaprat, D. and Di Paolo, T. (2001) Neuroprotective properties of 17β-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 41, 131-138
116. Phillis, J. W., Song, D. and O'Regan, M. H. (1998) Tamoxifen, a chloride channel blocker, reduces glutamate and aspartate release from the ischemic cerebral cortex. Brain Res. 780, 352-355
117. Shughrue, P. J. and Merchenthaler, I. (2003) Estrogen prevents the loss of CA1 hippocampal neurons in gerbils after ischemic injury. Neuroscience 116, 851-861
118. Kimelberg, H. K., Jin, Y., Charniga, C. and Feustel, P. J. (2003) Neuroprotective activity of tamoxifen in permanent focal ischemia. J. Neurosurg. 99, 138-142
119. Mehta, S. H., Dhandapani, K. M., De Sevilla, L. M., Webb, R. C., Mahesh, V. B. and Brann, D. W. (2003) Tamoxifen, a selective estrogen receptor modulator, reduces ischemic damage caused by middle cerebral artery occlusion in the ovariectomized female rat. Neuroendocrinology 77, 44-50
120. Kimelberg, H. K., Feustel, P. J., Jin, Y., Paquette, J., Boulos, A., Keller, R. W., Jr. and Tranmer, B. I. (2000) Acute treatment with tamoxifen reduces ischemic damage following middle cerebral artery occlusion. Neuroreport 11, 2675-2679
121. Kokiko, O. N., Murashov, A. K. and Hoane, M. R. (2006) Administration of raloxifene reduces sensorimotor and working memory deficits following traumatic brain injury. Behav. Brain Res. 170, 233-240
122. Rossberg, M. I., Murphy, S. J., Traystman, R. J. and Hurn, P. D. (2000) LY353381.HCl, a selective estrogen receptor modulator, and experimental stroke. Stroke 31, 3041-3046
123. Farr, T. D., Carswell, H. V., McCann, D. J., Sato, M., Bryant, H. U., Dodge, J. A. and Macrae, I. M. (2008) The selective oestrogen receptor modulator, LY362321, is not neuroprotective in a rat model of transient focal ischaemia. J. Neuroendocrinol. 20, 366-374
124. Schreihofer, D. A., Do, K. D. and Schreihofer, A. M. (2005) High-soy diet decreases infarct size after permanent middle cerebral artery occlusion in female rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 289, R103-R108
125. Burguete, M. C., Torregrosa, G., Perez-Asensio, F. J., Castello-Ruiz, M., Salom, J. B., Gil, J. V. and Alborch, E. (2006) Dietary phytoestrogens improve stroke outcome after transient focal cerebral ischemia in rats. Eur. J. Neurosci. 23, 703-710
126. Lovekamp-Swan, T., Glendenning, M. and Schreihofer, D. A. (2007) A high soy diet reduces programmed cell death and enhances bcl-xL expression in experimental stroke. Neuroscience 148, 644-652
127. Barrett-Connor, E. and Bush, T. L. (1991) Estrogen and coronary heart disease in women. JAMA, J. Am. Med. Assoc. 265, 1861-1867
128. Wenger, N. K., Speroff, L. and Packard, B. (1993) Cardiovascular health and disease in women. N. Engl. J. Med. 329, 247-256
129. Ho, J. Y., Chen, M. J., Sheu, W. H., Yi, Y. C., Tsai, A. C., Guu, H. F. and Ho, E. S. (2006) Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum. Reprod. 21, 2715-2720
130. Haberman, S., Capildeo, R. and Rose, F. C. (1981) Sex differences in the incidence of cerebrovascular disease. J. Epidemiol. Community Health 35, 45-50
131. Finucane, F. F., Madans, J. H., Bush, T. L.,Wolf, P. H. and Kleinman, J. C. (1993) Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. Arch. Intern. Med. 153, 73-79
132. Pedersen, A. T., Lidegaard, O., Kreiner, S. and Ottesen, B. (1997) Hormone replacement therapy and risk of non-fatal stroke. Lancet 350, 1277-1283
133. Billeci, A. M., Paciaroni, M., Caso, V. and Agnelli, G. (2008) Hormone replacement therapy and stroke. Curr. Vasc. Pharmacol. 6, 112-123
134. Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B. and Vittinghoff, E. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA, J. Am. Med. Assoc. 280, 605-613
135. Simon, J. A., Hsia, J., Cauley, J. A., Richards, C., Harris, F., Fong, J., Barrett-Connor, E. and Hulley, S. B. (2001) Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation 103, 638-642
136. Cherry, N., Gilmour, K., Hannaford, P., Heagerty, A., Khan, M. A., Kitchener, H., McNamee, R., Elstein, M., Kay, C., Seif, M. and Buckley, H. (2002) Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 360, 2001-2008
137. Lemaitre, R. N.,Weiss,N. S., Smith, N. L., Psaty, B.M., Lumley, T., Larson, E. B. and Heckbert, S. R. (2006) Esterified estrogen and conjugated equine estrogen and the risk of incident myocardial infarction and stroke. Arch. Intern. Med. 166, 399-404
138. Hodis, H. N., Mack, W. J., Lobo, R. A., Shoupe, D., Sevanian, A., Mahrer, P. R., Selzer, R. H., Liu Cr, C. R., Liu Ch, C. H. and Azen, S. P. (2001) Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 135, 939-953
139. Angerer, P., Stork, S., Kothny, W., Schmitt, P. and von Schacky, C. (2001) Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial. Arterioscler. Thromb. Vasc. Biol. 21, 262-268
140. Os, I., Hofstad, A. E., Brekke, M., Abdelnoor, M., Nesheim, B. I., Jacobsen, A. F., Birkeland, K., Larsen, A., Midtbo, K. and Westheim, A. (2000) The EWA (estrogen in women with atherosclerosis) study: a randomized study of the use of hormone replacement therapy in women with angiographically verified coronary artery disease. Characteristics of the study population. Effects on lipids and lipoproteins. J. Intern. Med. 247, 433-441
141. Binder, E. F., Williams, D. B., Schechtman, K. B., Jeffe, D. B. and Kohrt, W. M. (2001) Effects of hormone replacement therapy on serum lipids in elderly women. a randomized, placebo-controlled trial. Ann. Intern. Med. 134, 754-760
142. Kernan, W. N., Brass, L. M., Viscoli, C. M., Sarrel, P. M., Makuch, R. and Horwitz, R. I. (1998) Estrogen after ischemic stroke: clinical basis and design of The Women's Estrogen for Stroke Trial. J. Stroke Cerebrovasc. Dis. 7, 85-95
143. Viscoli, C. M., Brass, L. M., Kernan, W. N., Sarrel, P. M., Suissa, S. and Horwitz, R. I. (2001) A clinical trial of estrogen-replacement therapy after ischemic stroke. N. Engl. J. Med. 345, 1243-1249
144. Wassertheil-Smoller, S., Hendrix, S. L., Limacher, M., Heiss, G., Kooperberg, C., Baird, A., Kotchen, T., Curb, J. D., Black, H., Rossouw, J. E. et al. (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women';s Health Initiative: a randomized trial. JAMA, J. Am. Med. Assoc. 289, 2673-2684
145. Hendrix, S. L., Wassertheil-Smoller, S., Johnson, K. C., Howard, B. V., Kooperberg, C., Rossouw, J. E., Trevisan, M., Aragaki, A., Baird, A. E., Bray, P. F. et al. (2006) Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 113, 2425-2434
146. Anderson, G. L., Limacher, M., Assaf, A. R., Bassford, T., Beresford, S. A., Black, H., Bonds, D., Brunner, R., Brzyski, R., Caan, B. et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women';s Health Initiative randomized controlled trial. JAMA, J. Am. Med. Assoc. 291, 1701-1712
147. Craig, M. C., Maki, P. M. and Murphy, D. G. (2005) The Women's Health Initiative Memory Study: findings and implications for treatment. Lancet Neurol. 4, 190-194
148. Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones, III, B. N., Assaf, A. R., Jackson, R. D. et al. (2003) Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women';s Health Initiative Memory Study - a randomized controlled trial. JAMA, J. Am. Med. Assoc. 289, 2651-2662
149. Rapp, S. R., Espeland, M. A., Shumaker, S. A., Henderson, V. W., Brunner, R. L., Manson, J. E., Gass, M. L., Stefanick, M. L., Lane, D. S., Hays, J. et al. (2003) Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women';s Health Initiative Memory Study: a randomized controlled trial. JAMA, J. Am. Med. Assoc. 289, 2663-2672
150. Espeland, M. A., Rapp, S. R., Shumaker, S. A., Brunner, R., Manson, J. E., Sherwin, B. B., Hsia, J., Margolis, K. L., Hogan, P. E., Wallace, R. et al. (2004) Conjugated equine estrogens and global cognitive function in postmenopausal women: Women';s Health Initiative Memory Study. JAMA, J. Am. Med. Assoc. 291, 2959-2968
151. Shumaker, S. A., Legault, C., Kuller, L., Rapp, S. R., Thal, L., Lane, D. S., Fillit, H., Stefanick, M. L., Hendrix, S. L., Lewis, C. E. et al. (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women';s Health Initiative Memory Study. JAMA, J. Am. Med. Assoc. 291, 2947-2958
152. Heiss, G., Wallace, R., Anderson, G. L., Aragaki, A., Beresford, S. A., Brzyski, R., Chlebowski, R. T., Gass, M., LaCroix, A., Manson, J. E. et al. (2008) Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA, J. Am. Med. Assoc. 299, 1036-1045
153. Tannen, R. L., Weiner, M. G., Xie, D. and Barnhart, K. (2007) A simulation using data from a primary care practice database closely replicated the women's health initiative trial. J. Clin. Epidemiol. 60, 686-695
154. Vickers, M., Meade, T. and Darbyshire, J. (2002) WISDOM: history and early demise - was it inevitable? Climacteric 5, 317-325
155. Vickers, M. R., MacLennan, A. H., Lawton, B., Ford, D., Martin, J., Meredith, S. K., DeStavola, B. L., Rose, S., Dowell, A., Wilkes, H. C. et al. (2007) Main morbidities recorded in the women';s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 335, 239
156. Turgeon, J. L., McDonnell, D. P., Martin, K. A. and Wise, P. M. (2004) Hormone therapy: physiological complexity belies therapeutic simplicity. Science 304, 1269-1273
157. Utian, W. H. (2007) NIH and WHI: time for a mea culpa and steps beyond. Menopause 14, 1056-1059
158. Burger, H. G. (2007) WHI risks: any relevance to menopause management? Maturitas 57, 6-10
159. Clark, J. H. (2006) A critique of Women';s Health Initiative Studies (2002-2006). Nucl. Recept. Signaling 4, e023
160. Bath, P. M. and Gray, L. J. (2005) Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 330, 342
161. Sare, G. M., Gray, L. J. and Bath, P. M. (2008) Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur. Heart J. 29, 2031-2041
162. Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J. et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90, 1371-1388
163. Grey, A. B., Stapleton, J. P., Evans, M. C., Tatnell, M. A., Ames, R. W. and Reid, I. R. (1995) The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am. J. Med. 99, 636-641
164. Love, R. R., Wiebe,D.A., Feyzi, J. M., Newcomb, P.A. and Chappell, R. J. (1994) Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J. Natl. Cancer Inst. 86, 1534-1539
165. Bertelli, G., Venturini, M., Del Mastro, L., Garrone, O., Cosso, M., Gustavino, C., Cusimano, E., Guido, T., Nicolo, G. and Rosso, R. (1998) Tamoxifen and the endometrium: findings of pelvic ultrasound examination and endometrial biopsy in asymptomatic breast cancer patients. Breast Cancer Res. Treat. 47, 41-46
166. Heaney, R. P. and Draper, M. W. (1997) Raloxifene and estrogen: comparative bone-remodeling kinetics. J. Clin. Endocrinol. Metab. 82, 3425-3429
167. Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., Ravoux, A. C., Shah, A. S., Huster, W. J., Draper, M. and Christiansen, C. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337, 1641-1647
168. Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M. et al. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA, J. Am. Med. Assoc. 281, 2189-2197
169. Ettinger, B., Black, D. M., Mitlak, B. H., Knickerbocker, R. K., Nickelsen, T., Genant, H. K., Christiansen, C., Delmas, P. D., Zanchetta, J. R., Stakkestad, J. et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA, J. Am. Med. Assoc. 282, 637-645
170. Cauley, J. A., Norton, L., Lippman, M. E., Eckert, S., Krueger, K. A., Purdie, D. W., Farrerons, J., Karasik, A., Mellstrom, D., Ng, K. W. et al. (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res. Treat. 65, 125-134
171. Barrett-Connor, E., Cauley, J. A., Kulkarni, P. M., Sashegyi, A., Cox, D. A. and Geiger, M. J. (2004) Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J Bone Miner. Res. 19, 1270-1275
172. Mosca, L. (2001) Rationale and overview of the Raloxifene Use for the Heart (RUTH) trial. Ann. N.Y. Acad. Sci. 949, 181-185
173. Barrett-Connor, E., Mosca, L., Collins, P., Geiger, M. J., Grady, D., Kornitzer, M., McNabb, M. A. and Wenger, N. K. (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355, 125-137
174. Vogel, V. G., Costantino, J. P., Wickerham, D. L., Cronin, W. M., Cecchini, R. S., Atkins, J. N., Bevers, T. B., Fehrenbacher, L., Pajon, Jr, E. R., Wade, III, J. L. et al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, J. Am. Med. Assoc. 295, 2727-2741
175. Stroke Therapy Academic Industry Roundtable (STAIR) (1999) Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30, 2752-2758
176. Diener, H. C., Lees, K. R., Lyden, P., Grotta, J., Davalos, A., Davis, S. M., Shuaib, A., Ashwood, T.,Wasiewski, W., Alderfer, V., Hardemark, H. G. and Rodichok, L. (2008) NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 39, 1751-1758